Patents Expiring in December 2030
✉ Email this page to a colleague
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hisamitsu Pharm Co | SALONPAS | menthol; methyl salicylate | PATCH;TOPICAL | 022029-001 | Feb 20, 2008 | OTC | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
Hisamitsu Pharm Co | SALONPAS | menthol; methyl salicylate | PATCH;TOPICAL | 022029-002 | Nov 5, 2012 | OTC | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ||||
Glaxosmithkline | OJJAARA | momelotinib dihydrochloride | TABLET;ORAL | 216873-001 | Sep 15, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS | ||
Glaxosmithkline | OJJAARA | momelotinib dihydrochloride | TABLET;ORAL | 216873-002 | Sep 15, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS | ||
Glaxosmithkline | OJJAARA | momelotinib dihydrochloride | TABLET;ORAL | 216873-003 | Sep 15, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |